CAS Number68291-97-4
SynonymsExcegran; EINECS 200-659-6; 3-sulfamoylmethyl-1,2-benzisoxazole; 1-(1,2-benzisoxazol-3-yl)méthanesulfonamide; 3-sulfamoyl-methyl-1,2-benzisoxazol; 1-(1,2-Benzisoxazol-3-yl)methansulfonamid; Zonisamide; 1-(1,2-benzisoxazol-3-yl)methanesulfonamide; ad-810; Zonegran; exceglan; 1-(1,2-Benzoxazol-3-yl)methanesulfonamide; ZON; MFCD00865316; Excemide; 1,2-Benzisoxazole-3-methanesulfonamide; excegram; ci-912
Molecular FormulaC8H8N2O3S
Molecular Weight212.23
Purity99%
Density1.5±0.1 g/cm3
Boiling Point457.2±47.0 °C at 760 mmHg
Melting Point275°C dec.
Appearanceoff-white powder
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 68291-97-4 |
| Catalog No. | 2A-9013005 |
| Chinese Name | 唑尼沙胺 |
| Synonyms | Excegran; EINECS 200-659-6; 3-sulfamoylmethyl-1,2-benzisoxazole; 1-(1,2-benzisoxazol-3-yl)méthanesulfonamide; 3-sulfamoyl-methyl-1,2-benzisoxazol; 1-(1,2-Benzisoxazol-3-yl)methansulfonamid; Zonisamide; 1-(1,2-benzisoxazol-3-yl)methanesulfonamide; ad-810; Zonegran; exceglan; 1-(1,2-Benzoxazol-3-yl)methanesulfonamide; ZON; MFCD00865316; Excemide; 1,2-Benzisoxazole-3-methanesulfonamide; excegram; ci-912 |
| Molecular Formula | C8H8N2O3S |
| Molecular Weight | 212.23 |
| Purity | 99 |
| Density | 1.5±0.1 g/cm3 |
| Boiling Point | 457.2±47.0 °C at 760 mmHg |
| Melting Point | 275°C dec. |
| Appearance | off-white powder |
| Water Solubility | H2O: >5 mg/mL, soluble |
| Storage Condition | Store in a sealed container in a cool, dry place. |
| Application | Zonisamide is a 1,2-benzenisoxazole derivative with anti-epileptic activity. |
| HTC | 2935009090 |
| MDL Number | MFCD00865316 |
| SMILES | [S](=O)(=O)(N)Cc1n[o]c2c1cccc2 |
| InChI | 1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12) |
| InChI Key | UBQNRHZMVUUOMG-UHFFFAOYSA-N |
| NACRES Code | NA.24 |
| UNSPSC | 41116107 |
| MSDS | msds/13005_1_68291_97_4.pdf |
| Bioactivity | Zonisamide is a 1,2 benzisoxazole derivative and the first agent of this chemical class to be developed as an antiepileptic drug.Target: Calcium channel inhibitor; Sodium channel inhibitorZonisamide is a sulfonamide anticonvulsant approved for use as an adjunctive therapy in adults with partial-onset seizures for adults; infantile spasm, mixed seizure types of Lennox-Gastaut syndrome, myoclonic, and generalized tonic clonic seizure. Zonisamide is a 1,2 benzisoxazole derivative and the first agent of this chemical class to be developed as an antiepileptic drug. It has shown activity in various animal models of epilepsy, and although a detailed mode of action awaits clarification it appears to block the propagation/spread of seizure discharges and to suppress the epileptogenic focus [1].Zonisamide 500 mg/day was significantly superior to placebo in reducing the frequency of complex partial seizures (-51% versus -16%), all partial seizures and all seizures, with dose-dependent benefit provided over a 100-500 mg/day dose range. Supporting trials have confirmed significant increases in reduction in median seizure frequency (up to 41%) and responder rates (35-42%) compared with placebo following zonisamide 400-600 mg/day, enabling 20-27% of patients to attain >or=75% reduction in seizure frequency [2].Clinical indications: Epilepsy; Lewy body dementia; Parkinsons diseaseToxicity: Anorexia; Somnolence; Dizziness; Irritability; Confusional state; Depression; Diplopia; Memory impairment Related Catalog Signaling Pathways >> Membrane Transporter/Ion Channel >> Calcium Channel Signaling Pathways >> Membrane Transporter/Ion Channel >> Sodium Channel Research Areas >> Neurological Disease References [1]. Peters DH, et al. Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy. Drugs. 1993 May;45(5):760-87. [2]. Brodie MJ, et al. Zonisamide as adjunctive therapy for refractory partial seizures. Epilepsy Res. 2006 Feb;68 Suppl 2:S11-6. Epub 2005 Nov 28. Chemical & Physical Properties Density 1.5±0.1 g/cm3 Boiling Point 457.2±47.0 °C at 760 mmHg Melting Point 275°C dec. Molecular Formula C8H8N2O3S Molecular Weight 212.226 Flash Point 230.3±29.3 °C Exact Mass 212.025558 PSA 94.57000 LogP -0.10 Vapour Pressure 0.0±1.1 mmHg at 25°C Index of Refraction 1.656 InChIKey UBQNRHZMVUUOMG-UHFFFAOYSA-N SMILES NS(=O)(=O)Cc1noc2ccccc12 Water Solubility H2O: >5 mg/mL, soluble |
| Use of | Properties Articles32 Name zonisamide Synonym More Synonyms Zonisamide Biological Activity Related Catalog Signaling Pathways >> Membrane Transporter/Ion Channel >> Calcium Channel Signaling Pathways >> Membrane Transporter/Ion Channel >> Sodium Channel Research Areas >> Neurological Disease References [1]. Peters DH, et al. Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy. Drugs. 1993 May;45(5):760-87. [2]. Brodie MJ, et al. Zonisamide as adjunctive therapy for refractory partial seizures. Epilepsy Res. 2006 Feb;68 Suppl 2:S11-6. Epub 2005 Nov 28. Chemical & Physical Properties Molecular Formula C8H8N2O3S Exact Mass 212.025558 PSA 94.57000 LogP -0.10 Index of Refraction 1.656 InChIKey UBQNRHZMVUUOMG-UHFFFAOYSA-N |
| Tax Rebate | 9.0% |
| Supervision | None MFN tariff: 6.5% Ordinary tariff: 35.0% |
| Transport Info | Product name: Purity: 98.0% |
| MSDS Transport Info | Module 14. Shipping information United Nations classification: inconsistent with United Nations classification standards UN number: not specified |
| Related Products in Specialty Chemicals | ||
|---|---|---|
| Zofenopril | 81872-10-8 | 2A-9012998 |
| Zofenopril calcium | 81938-43-4 | 2A-9012999 |
| Zolasartan | 145781-32-4 | 2A-9013000 |
| Zolertine | 4004-94-8 | 2A-9013001 |
| Zolimomabaritox | 141483-72-9 | 2A-9013002 |
| Zorubicin HCl | 36508-71-1 | 2A-9013006 |
| (+)-Dibenzoyl-D-tartaric acid | 17026-42-5 | 2A-9013008 |
| (3-Chlorophenyl)propan-1-one | 34841-35-5 | 2A-9013011 |
| (4-Iso-propylphenyl)ethanone | 645-13-6 | 2A-9013012 |
| 1-(2-(2-methoxyethoxy)ethoxy)-Butane | 7382-32-3 | 2A-9013021 |
| Browse all Specialty Chemicals products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS